Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.
about
Exploring alternative treatments for Helicobacter pylori infectionOne-step chromatographic purification of Helicobacter pylori neutrophil-activating protein expressed in Bacillus subtilisHigh yield purification of Helicobacter pylori neutrophil-activating protein overexpressed in Escherichia coliHelicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications.Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.Inhibition of the Aurora A kinase augments the anti-tumor efficacy of oncolytic measles virotherapy.Differential effects of DEAE negative mode chromatography and gel-filtration chromatography on the charge status of Helicobacter pylori neutrophil-activating protein.Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein.An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.Inflammation, immunity, and vaccine development for Helicobacter pylori.Inflammation, immunity, and vaccines for Helicobacter pylori infection.RNA-based viral vectors.Immunology and vaccines and nanovaccines for Helicobacter pylori infection.Vaccine platform recombinant measles virus.Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects.Potential and clinical translation of oncolytic measles viruses.Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.Development of Recombinant Measles Virus-Based Vaccines.Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.One-step Negative Chromatographic Purification of Helicobacter pylori Neutrophil-activating Protein Overexpressed in Escherichia coli in Batch Mode.Production and delivery of Helicobacter pylori NapA in Lactococcus lactis and its protective efficacy and immune modulatory activity.
P2860
Q26828017-EA1ABC36-740C-4B8D-ADB7-5DCB1B351C39Q28486064-2D8E53D9-C895-4FCA-9E12-F22971AA55EFQ28647787-A1F1DB3A-DA21-4D61-9C5F-16274BA03D74Q33594856-8A89D33A-8813-4B40-9578-7A8B3390FE4FQ36014057-C8440308-8002-425A-A5D1-F7CFCFDDE546Q36108892-B41CE712-FC39-4775-80DF-F55D66987675Q36318284-83956D65-E654-48EE-84F2-C5DE3891D1FCQ36952684-25CDB725-DEDD-4A58-ACD2-C2B642AFD610Q37316842-F8E930CB-725B-448E-A5B3-40E177464077Q37520259-83F12BDB-7B31-4303-98B1-1C53617E0E92Q37927421-A320FCA8-FD5E-4E4B-A44D-5CABC1A08FE6Q38041639-7AA655A8-DB1D-4974-9636-B60645E0CDE6Q38266413-F951934D-B252-4DF8-AA5D-8A97AC49B4F3Q38341782-DE489C88-2DC4-48E7-BFBF-884BB8F6217AQ38657271-E6239E6F-FBDB-408F-A370-76F6F8681DC7Q38754467-7782C5F8-7D3E-473C-8458-310CA6C82761Q38764947-87D6D315-C4E7-4C07-ACCC-8B698083FFF2Q39221090-1E4CE91A-FBC1-4411-AE60-0DDB82A2C6EBQ40259612-42C494AF-90E4-4480-8007-31C4147441F4Q41557807-29C3EC06-9BEB-4EDF-B55C-F3EB8901AEDCQ51647134-D96B26D1-3D03-4913-8F98-5781432CAC7AQ54228847-41F9ECCE-4F9B-40EB-957F-FE94A7C448B8
P2860
Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@ast
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@en
type
label
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@ast
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@en
prefLabel
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@ast
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@en
P2860
P1433
P1476
Immunogenicity of attenuated m ...... neutrophil-activating protein.
@en
P2093
Ianko D Iankov
P2860
P304
P356
10.1016/J.VACCINE.2010.12.020
P407
P577
2010-12-21T00:00:00Z